Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

New England Journal of Medicine

Volumn 349, Issue 20, 2003, Pages 1893-1906

  Pfeffer, Marc A ^a   McMurray, John J V ^b   Velazquez, Eric J ^c   Rouleau, Jean Lucien ^d   Køber, Lars ^e   Maggioni, Aldo P ^f   Solomon, Scott D ^a   Swedberg, Karl ^g   Van de Werf, Frans ^h   White, Harvey ⁱ   Leimberger, Jeffrey D ^c   Henis, Marc ^j   Edwards, Susan ^k   Zelenkofske, Steven ^k   Sellers, Mary Ann ^c   Califf, Robert M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WESTERN INFIRMARY   (United Kingdom)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MONTREAL HEART INSTITUTE   (Canada)

^e Rigshospitalet   (Denmark)

^f ANMCO RESEARCH CENTER   (Italy)

^g SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^h Leuven Coordinating Center   (Belgium)

ⁱ GREEN LANE HOSPITAL   (New Zealand)

^j Medical Pharmaceutical Consultants   (United States)

^k NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VALSARTAN;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATALITY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RASH; SIDE EFFECT; SURVIVAL; TASTE DISORDER;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0242490542     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa032292     Document Type: Article

References (30)

1. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669-77.
2. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of Iisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343:1115-22.
3. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995;345:669-85.
4. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995;345:686-7.
5. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80-5.
6. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
8. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995;333:1670-6.
9. Pfeffer MA. ACE inhibition in acute myocardial infarction. N Engl J Med 1995;332:118-20.
10. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000;355:1575-81.
11. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996;334:1649-54.
12. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM, McMurray, JJ. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 2001;37:1056-61.
13. Horiuchi M, Akishita M, Dzau VJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 1999;33:613-21.
14. Pfeffer MA, McMurray J, Leizorovicz A, et al. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Am Heart J 2000;140:727-50.
15. Sidak Z. Rectangular confidence regions for the means of multivariate normal distributions. J Am Stat Assoc 1967;62:626-33.
16. Fisher LD. Active control trials: what about a placebo? A method illustrated with clopidogrel, aspirin and placebo. J Am Coll Cardiol 1998;31:Suppl A:49A. abstract.
17. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-control trials. Drug InfJ 2001;35:435-49.
18. Velazquez EJ, Pfeffer MA, McMurray JV, et al. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003;5:537-44.
19. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001;38:2101-13.
20. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart faflure. Eur Heart J 2001;22:1527-60. [Erratum, Eur Heart J 2001;22:2217-8.]
21. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart faflure. Eur Heart J 2001;22:1527-60. [Erratum, Eur Heart J 2001;22:2217-8.]
22. Skali H, Pfeffer MA. Prospects for ARB in the next five years. J Renin Angiotensin Aldosterone Syst 2001;2:215-8.
23. Committee for Proprietary Medicinal Products. Points to consider on switching between superiority and non-inferiority. Br J Clin Pharmacol 2001;52:223-8.
24. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003;22:169-86.
25. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
26. McMurray JJV, Östergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767-71.
27. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003;362:759-66.
28. Yusuf S. From the HOPE to the ONTAR-GET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A.
29. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002;360:752-60.
30. Dickstein K. What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J 2003;145:754-7.